{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-23-000004","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.054356+00:00","generated_at":"2026-06-12T02:22:26.226894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rallybio Q2 net loss $18.6M; cash $137.8M; CEO transition to Stephen Uden","bullets":["Net loss $18.6M ($0.46/sh) vs $17.6M ($0.57/sh) in Q2 2022; R&D expense $13.1M, up from $10.1M.","Cash, equivalents and marketable securities $137.8M as of June 30, providing runway into 1Q 2025.","RLYB212 Phase 1b proof-of-concept met endpoint; multiple-dose cohort data and tox results expected in 4Q 2023.","RLYB116 Phase 1 MAD study initial data (safety, PK, PD) and indication strategy expected in 4Q 2023.","Effective Aug 1, Stephen Uden became CEO; Martin Mackay appointed Executive Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-23-000004","json":"https://secwatch.observer/filing/0001739410-23-000004.json","markdown":"https://secwatch.observer/filing/0001739410-23-000004.md","text":"https://secwatch.observer/filing/0001739410-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/0001739410-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/rlyb-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:22:26.226894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe002fe874fa603287dc915c1ee2afcd27383b81","claim":"Rallybio Corp reported the second quarter ended June 30, 2023 results: net income Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46, EPS $0.46.","evidence_excerpt":"On August 8, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/0001739410-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46"},{"label":"EPS","value":"$0.46"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}